Goncalves Joana 4

What Happened

• Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, exercised stock derivatives to acquire 7,000 shares (3,500 @ $6.84 and 3,500 @ $7.80) for a total cash outlay of $51,240.
• On the same day (2026-06-15) she sold shares in open-market transactions: 1,636 @ $68.38, 5,064 @ $69.42, 300 @ $70.62 and 947 @ $69.69 — total proceeds reported $550,606.
• The filing also shows two derivative "disposed" entries of 3,500 shares each at $0.00 (reported as derivative dispositions) for $0 proceeds; these relate to exercise/settlement activity recorded on the Form 4.

Key Details

• Transaction date: 2026-06-15 (Form filed same day; no late filing indicated).
• Acquisitions: 7,000 shares via exercise — 3,500 @ $6.84 ($23,940) and 3,500 @ $7.80 ($27,300); total cost $51,240.
• Open-market sales: total 7,947 shares for aggregate proceeds of $550,606 (individual sales and weighted-average prices listed above).
• Additional derivative dispositions: two entries of 3,500 shares each at $0.00 (reported as disposals of derivatives).
• Notable footnotes: sales were effected under a Rule 10b5-1 trading plan (entered 9/19/2025) (F2); reported sale prices are weighted averages across price ranges (F3–F5); an automatic sell-to-cover procedure for tax withholding is referenced (F6); the filer acquired 288 shares under the company stock purchase plan on June 8, 2026 (F1). Vesting schedules for the option/warrant are noted (F7, F8).
• Shares owned after the transactions: not provided in the materials you supplied.

Context

• The filing shows exercises followed by same-day sales, which commonly reflect cashless-exercise or pre-planned disposition activity; here the sales were controlled under a 10b5-1 plan per the filing.
• The $0.00 derivative disposal lines typically indicate net settlement or other non-cash derivative treatment recorded on Form 4; footnotes and the company's records would clarify the mechanics (the reporting person has offered to provide detailed per-price breakdowns on request).
• These are insider transactions by an executive (not a registered 10% owner); sales under a 10b5-1 plan and sell-to-cover tax actions are routine and do not, by themselves, imply a change in view on the company.